Non-canonical peptides bound to MHC
dc.contributor.author | Day, S. | |
dc.contributor.author | Ramsland, Paul | |
dc.contributor.author | Apostolopoulos, V. | |
dc.date.accessioned | 2017-01-30T13:49:59Z | |
dc.date.available | 2017-01-30T13:49:59Z | |
dc.date.created | 2016-09-12T08:36:53Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Day, S. and Ramsland, P. and Apostolopoulos, V. 2009. Non-canonical peptides bound to MHC. Current Pharmaceutical Design. 15 (28): pp. 3274-3282. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/35489 | |
dc.identifier.doi | 10.2174/138161209789105090 | |
dc.description.abstract |
Central to the initiation of a T cell dependent immune response is the recognition of major histocompatibility complex (MHC) class I or class II molecules (in humans termed HLA and in mice termed H-2) bound to antigenic peptide. T cell receptors (TCR) have programmed specificity for particular peptide/MHC complexes, which ensures focused immune responses are generated against the antigen source. To design effective peptide based vaccines a comprehensive understanding of the specific interactions between MHC molecules and peptide, and of TCR recognition of MHC/peptide is valuable. We place particular emphasis on non-canonical bound peptides and their use in immunotherapy studies. © 2009 Bentham Science Publishers Ltd. | |
dc.title | Non-canonical peptides bound to MHC | |
dc.type | Journal Article | |
dcterms.source.volume | 15 | |
dcterms.source.number | 28 | |
dcterms.source.startPage | 3274 | |
dcterms.source.endPage | 3282 | |
dcterms.source.issn | 1381-6128 | |
dcterms.source.title | Current Pharmaceutical Design | |
curtin.department | School of Biomedical Sciences | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |